TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02944110

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon receptor antagonist LY2409021
Description: single oral dose of 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon receptor antagonist LY2409021
Description: single oral dose of 300mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo tablets
Study: NCT01048593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: Single intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: Single intraocular injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Description: Single intraocular injection
Study: NCT00801957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus ointment 0.03%
Description: topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone acetate ointment 1%
Description: topical application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone butyrate ointment 0.1%
Description: topical application

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningitec
Description: im injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec
Description: im injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Meningitec
Description: im injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AC VAX
Description: im injection

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AC VAX
Description: im injection

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AC VAX
Description: im injection
Study: NCT03537989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: To reduce the volume of saline administered during surgery of the colon and the rectum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: To reduce the volume of saline administered during surgery of the colon and the rectum
Study: NCT05106959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Informed Shame Resilience Training
Description: Shame resilience involves four elements. Understating shame, normalizing shame thoughts, reaching out, and speaking shame. Motivational interviewing will be used to elicit and guide participants through these four elements.
Study: NCT02452736

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
Study: NCT03063528

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Physical Activity
Description: Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction and Management
Description: Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph.
Study: NCT03560037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision Assisted Colonoscopy
Description: Detachable device that is fixed to the end of colonoscope. The device has single-row of soft, hair-like projections that flatten colonic folds during colonoscope withdrawal which can aid in detection of colon polyps.
Study: NCT03882021

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A specific electrophysiology mapping protocol is applicable with the GRID catheter.
Description: The procedure will be done according to a standard ablation approach. During the electrophysiology study, additional mapping data will be collected to support the study endpoints using the GRID catheter.
Study: NCT03538197

Intervention type: OTHER
Group type: OTHER
Intervention: clinical and biological correlates
Description: To measure the rate of suicidal re attempt (SR) in a population of young adults aged 18 to 25 years.~To identify sociodemographic, clinical and biological characteristics of a population of suicidal young people, in an attempt to highlight potential risk factors
Study: NCT01742143

Intervention type: BEHAVIORAL
Intervention: The Integrated Cancer Care Access Network (ICCAN)
Description: Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Intervention type: BEHAVIORAL
Intervention: The Integrated Cancer Care Access Network (ICCAN)
Description: Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance.

Intervention type: BEHAVIORAL
Intervention: Usual and Customary Group (U&C)
Description: Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.~Chart review at 3 mo, 6 mo and 1 year, and as needed.
Study: NCT03792659

Intervention type: OTHER
Intervention: Blood Sample Draw
Description: Approximately 100 cc (less than 1/2 cup) of blood will be drawn from both groups.
Study: NCT04756310

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Retilut
Description: antioxidants, antiangiogenic, antiinflammatory micronutrients

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Theavit
Description: antioxidants micronutrients
Study: NCT00939549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide/Glatiramer acetate
Description: Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
Study: NCT03456128

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAPABLE
Description: It involves up to 10 in-home tailored interventions of approximately 60 minutes duration each over a 5-month period. The assessment driven interventions are delivered by an Occupational Therapist (OT) (≤ 6 home visits for ≤ 1hour), a Registered Nurse (RN) (≤ 4 home visits for ≤ 1hour), and a handyman (HM) team.
Study: NCT03293615

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exploration
Description: Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exploration
Description: Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
Study: NCT03926208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Soak and Scrub
Description: Betadine soak and scrub in addition to standard clorhexadine scrub (standard of care).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clorhexadine scrub
Description: Clorhexadine scrub (standard of care).
Study: NCT02968134

Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
Study: NCT03858179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBMT
Description: PBMT will be applied bilaterally using the direct contact method with light pressure on the skin to 6 sites of the anterior thigh (2 medial, 2 lateral, and 2 central). A 12-diode cluster, with 4 905-nm laser diodes (12.5W peak power for each diode), 4 875-nm LED diodes (17.5 mW mean power for each diode), and 4 640-nm LED diodes (15 mW mean power for each diode), manufactured by Multi Radiance Medical® (Solon, OH, USA), will be used to apply the PBMT. The dose used for applications during the training and/or detraining periods will be 30 Joules (J) per site (180 J per thigh). PBMT will be applied before each workout and during the detraining period, depending on the group to which the volunteers are allocated.
Study: NCT04027192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 tablet
Description: 50 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 tablet
Description: 50 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 tablet
Description: 50 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 tablet
Description: 50 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2328065 tablet
Description: 50 mg tablet, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo LSF
Description: Matching Placebo LSF, orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Matching Placebo tablet, orally
Study: NCT03916133

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Intervention group
Description: 6s PBV mapping will be conducted
Study: NCT03373123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopy
Description: Endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTA
Description: Radiomic features were extracted from CTA images.
Study: NCT04665453

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Recording of the brain electrical activity during sleep; background activity and sleep phases will be evaluated

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of vital functions
Description: Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of vital functions
Description: Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Monitoring of vital functions
Description: Measuring of respiratory rate, heart rate, SpO2, every 10 minutes after the medicine is given to the patient for the duration of EEG, and after 120 minutes. Blood pressure is measured at the time of application of the medicine, at the end of EEG and after 120 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 0,1mg/kg oral syrup
Description: Melatonine in the form of syrup will be given orally to child.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 mcg/kg sublingually
Description: Dexmedetomidine in the form of a solution will be given to child sublingually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 3 mcg/kg intranasally
Description: Dexmedetomidine in the form of nasal spray will be given to child intranasally.
Study: NCT04438486

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: specific dietary advice for Hyperuricemia

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Group B
Description: Barely Green（three times a day, 5g(10 tablets)） dietary advice for Hyperuricemia as Group A
Study: NCT04137068

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reduced Activity
Description: Participants reduce their activity level to \<5,000 steps/day and \<50 % of baseline steps.
Study: NCT03882294

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be requested to consume the drinks (80 ml) twice a day - after lunch and dinner for 12 weeks.
Study: NCT03297450

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aphasia therapy
Description: Based on linguistic tests, individualized aphasia therapy will be provided

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-tDCS
Description: tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
Study: NCT04163562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INP20
Description: Part A: Oral INP20 administration at ascending doses once daily for 2 weeks. Part B: Two doses of oral INP20 derived from Part A once daily for 6 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A: Oral placebo administration onces daily for 2 weeks. Part B: Oral placebo administration onces daily for 6 months.
Study: NCT03853473

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning
Description: Remote Ischemic Preconditioning (RIPC) occurs when a limb is made transiently ischemic (5 minutes) using a simple blood pressure cuff. We are proposing that study participants in the RIPC group perform the intervention daily at home for at least 14 days prior to scheduled surgery. They will inflate a blood pressure cuff on the upper portion of their nondominant arm, inflate it to 225 mmHg for 5 minutes, release the cuff for 5 minutes, and repeat this 5 times (for a total of 45 minutes). A study coordinator will monitor compliance with phone calls and daily log sheets that must be filled out.
Study: NCT04575155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEAM Strategy
Description: 1. Pharmacists will have read/write EHR access with established Epic security points~2. Pharmacists will initiate medication reconciliation activities by calling the patient for a Comprehensive Medication Review. Pharmacists will add notes in their medication list for the prescriber, requesting the removal or discontinuation of prescribed drugs that patients report they are not taking and adding medications omitted from the provider's list. The pharmacist will provide notifications via secured Epic messaging direct to prescribers of any patient concerns.~3. At 6 month if poor adherence is determined, the pharmacist will initiate Therapy Management Review which is a call from the pharmacist to the patient specifically about the medication(s) for which they have poor adherence. If necessary, the pharmacist will create notes and send an in-basket message to the prescriber.~4. The prescriber will make changes to the patient's EHR and/or contact the patient as they see fit.
Study: NCT04198870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MitraClip™ device implantation
Description: Transcatheter repair of the mitral valve using MitraClip™ device

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mitral Valve Repair Surgery
Description: Surgical repair of the mitral valve
Study: NCT04005378

Intervention type: OTHER
Group type: OTHER
Intervention: CSC Step-down intervention
Description: Web-based telemedicine and a smartphone app, to decrease disengagement likelihood

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: Usual Care provided by CSC center
Study: NCT01349543

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV A Memphis 37
Description: Intranasal administration
Study: NCT04418024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG10
Description: TTR stabilizer administered orally twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active control
Study: NCT04097470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: Decitabine dosage 20mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine dosage 20mg/m2 i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 50 mg b.i.d.
Study: NCT03873883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EOS100850
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Standard of Care IV Infusion
Study: NCT01690143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
Study: NCT03255603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 Supplementation
Description: Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 Supplementation
Description: Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Starch Type 4 Supplementation
Description: Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Digestible Starch Supplementation
Description: Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
Study: NCT02187848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR408701
Description: Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous